Partners Eisai and Biogen ($BIIB) are moving their oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III. | Partners Eisai and Biogen are moving their oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III.